Sellas Life Sciences Group Inc (NASDAQ: SLS) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company released clinical data that looked to be overwhelmingly positive. However, as you will see below, things aren’t always as they seem. Today, we’ll talk about:
- The data release;
- what we’re seeing from SLS as a result;
- risks to consider; and
- what we’ll be watching for ahead.
SLS Heads For The Top On What Seems To Be Positive Data
As mentioned above, Sellas Life Sciences is having an incredibly strong start to the trading session this morning after announcing what seemed to be positive clinical data. In a press release issued early this morning, the company announced positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of trastuzumab +/- (NeuVaxTM) in HER2 1+/2+ breast cancer patients.
in the release, SLS said that the pre-specified interim analysis demonstrated a clinically meaningful difference in median disease-free survival in favor of the active arm (NeuVax + Herceptin), which was a primary endpoint of the study. In a statement, Angelos Stergiou, MD, ScD h.c., President and CEO at SLS, had the following to offer:
We are indeed excited about these compelling results and believe NeuVax + Herceptin has the potential to become an important therapeutic option for TNBC patients. The positive NeuVax phase 2b data underscores the innovative science and approach we have taken to investigate this agent’s potential to address this persistent therapeutic challenge. We plan to immediately engage with the FDA and EMA, as per the recommendation of the DSMB, to identify the optimal path forward in this particular patient group, while advancing the drug through a partnership or other strategic collaboration…These are indeed unique and exciting clinical data for TNBC patients, and I would like to extend my sincere gratitude to all patients who have participated in this clinical trial, as well as the study teams.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the news proved to be overwhelmingly positive (at least seemingly so – we’ll get into that later). So, it’s no surprise to see that excited investors are pushing Sellas Life Sciences to the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:03), SLS is trading at $5.58 per share after a gain of $2.13 per share (61.74%) thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!